Compare LYFT Inc (LYFT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Tango Therapeutics Inc. — how do they compare? LYFT Inc trades at $16.42 (market cap $6.20B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: LYFT Inc is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| LYFT | TNGX | |
|---|---|---|
Market Cap | $6.20B | $3.75B |
Volume | 12,306,511 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $24.57 | $32.90 |
52-Week Low | $12.65 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $16.38, up 1.68% with a bullish technical signal. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, though recent earnings missed expectations. Positive developments include European expansion and a major partnership with Sphere Entertainment. Cash flow improved significantly to $891M in 2025 from negative levels in prior years.
Lyft presents a mixed outlook with strong fundamentals but execution risks. The stock trades below analyst consensus target of $18.07, offering potential upside. Key risks include regulatory challenges from the $272.5M driver classification settlement and competitive pressures. Institutional sentiment leans cautious with 58% hold ratings despite improving financial metrics.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
